Inhibikase Therapeutics, Inc.
IKTInhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing disease-modifying therapeutics for cardiopulmonary and neurodegenerative diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing disease-modifying therapeutics for cardiopulmonary and neurodegenerative diseases. The company's primary value proposition lies in its proprietary prodrug technology, which is designed to improve the safety, tolerability, and systemic exposure of established protein kinase inhibitors.
The company is a clinical-stage developer positioning its lead candidate as a potentially superior, disease-modifying oral alternative to existing PAH treatments through improved GI tolerability.
Questions, answered.
- What is Inhibikase Therapeutics, Inc.'s market cap?
- Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $269.3M and trades on NASDAQ.
- Who are Inhibikase Therapeutics, Inc.'s competitors?
- Inhibikase Therapeutics, Inc.'s key competitors include United Therapeutics, Gossamer Bio, Liquidia Corporation, and others. These companies compete in similar markets and product categories.
- Who does Inhibikase Therapeutics, Inc. partner with?
- Inhibikase Therapeutics, Inc.'s notable partners include ABLi Therapeutics, Inc., Sphaera Pharma Pte. Ltd., Pivot Holding LLC.
- What subsidiaries does Inhibikase Therapeutics, Inc. have?
- Inhibikase Therapeutics, Inc.'s subsidiaries include CorHepta Pharmaceuticals, Inc..
- Where is Inhibikase Therapeutics, Inc. headquartered?
- Inhibikase Therapeutics, Inc. is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2020.